R&D | January 14, 2026
Avista Therapeutics unveils AI-powered expansion of gene therapy platform
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Rising demands and advancements in eye care drive growth
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
